Story Content

Tokyo: With a very promising development, which will transform the lives of over 500 million diabetic patients all over the world, researchers at Kumamoto University in Japan have developed a new type of insulin pill that will help remove the need to inject patients with insulin every day.

More than a hundred years of stomach acids and digestive enzymes killing insulin before it could enter the bloodstream have caused patients to have to use needles. Led by Associate Professor Shingo Ito, this team has created a small intestine-permeable cyclic peptide (DNP peptide), which aids in insulin to pass through the gut wall unharmed.

The insulin formulation taken orally (in oral bioavailability tests published in Molecular Pharmaceutics) exhibited high bioavailability (33741 percent relative to injections) and had an effect comparable to insulin by lowering blood sugar levels in diabetic mice with no significant side effects.

The technology is compatible with zinc-stabilized insulin hexamer and has demonstrated compatibility with long-acting formulations as well. Now the researcher is progressing to larger animal models and human intestinal simulations, and now the needle-free future seems nearer.

This innovation has the potential to revolutionize diabetes care, enhancing treatments and quality of life outcomes in patients.